MINI FUTURE LONG - NOVO-NORDISK B | Market Closed - Euronext Paris 12:30:02 2024-05-17 EDT | ||
| 2.68 EUR | -5.96% |
|
| 1 month | +20.18% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 2.68 | -5.96% |
| 24-05-16 | 2.85 | -2.06% |
| 24-05-15 | 2.91 | +3.19% |
| 24-05-14 | 2.82 | +1.08% |
| 24-05-13 | 2.79 | +14.34% |
Real-time Euronext Paris
Last update May 17, 2024 at 12:30 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| R05NB | |
| ISIN | NLBNPNL2P6P5 |
| Date issued | 2024-03-22 |
| Strike | 704.9 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.5 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.955 € |
|---|---|
| Lowest since issue | 1.72 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
903.3
DKK
Average target price
909.2
DKK
Spread / Average Target
+0.66%
- Stock Market
- Certificates
- R05NB Certificat
